Search Results - "Obi, Engels N."

Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction by Mohanty, April F, Levitan, Emily B, King, Jordan B, Dodson, John A, Vardeny, Orly, Cook, James, Herrick, Jennifer S, He, Tao, Patterson, Olga V, Alba, Patrick R, Russo, Patricia A, Obi, Engels N, Choi, Michelle E, Fang, James C, Bress, Adam P

“…Background Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for…”
Get full text

Recurrent Clostridioides difficile infection worsens anxiety-related patient-reported quality of life by Hengel, Richard L., Schroeder, Claudia P., Jo, Jinhee, Ritter, Timothy E., Nathan, Ramesh V., Gonzales-Luna, Anne J., Obi, Engels N., Dillon, Ryan J., Van Anglen, Lucinda J., Garey, Kevin W.

“…Background Clostridioides difficile infection (CDI) is associated with high recurrence rates impacting health-related quality of life (HrQOL). However,…”
Get full text

Incidence of acute kidney injury (AKI) and its impact on patient outcomes among adult hospitalized patients with carbapenem-resistant Gram-negative infections who received targeted treatment with a newer β-lactam or β-lactam/β-lactamase inhibitor-, polymyxin- or aminoglycoside-containing regimen by Lodise, Thomas P, Yucel, Emre, Obi, Engels N, Watanabe, Alexandre H, Nathanson, Brian H

“…Abstract Background Limited comparative data exist on acute kidney injury (AKI) risk and AKI-associated outcomes in hospitalized patients with…”
Get full text

Comparative evaluation of early treatment with ceftolozane/tazobactam versus ceftazidime/avibactam for non-COVID-19 patients with pneumonia due to multidrug-resistant Pseudomonas aeruginosa by Lodise, Thomas P, Obi, Engels N, Watanabe, Alexandre H, Yucel, Emre, Min, Jae, Nathanson, Brian H

“…Ceftolozane/tazobactam and ceftazidime/avibactam are commonly used in patients with MDR-Pseudomonas aeruginosa (PSA) pneumonia (PNA). This study compared…”
Get full text

Risk assessment of post-discharge mortality among recently hospitalized Medicare heart failure patients with reduced or preserved ejection fraction by Stampehl, Mark, Friedman, Howard S., Navaratnam, Prakash, Russo, Patricia, Park, Siyeon, Obi, Engels N.

“…Objective: Targeted care management for hospitalized patients with acute decompensated heart failure (ADHF) with reduced or preserved ejection fraction…”
Get full text

Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States by Jiang, Yiling, Sarpong, Eric M., Sears, Pamela, Obi, Engels N.

“…Introduction Fidaxomicin is as effective as vancomycin in treating Clostridioides difficile infection (CDI) but more effective at preventing recurrence…”
Get full text

Adoption and Trends in Uptake of Updated ICD-10 Codes for Clostridioides difficile—A Retrospective Observational Study by Deshpande, Abhishek, Chen, Yiyun, Boye-Codjoe, Eugenia, Obi, Engels N

“…Abstract Background In October 2017, the single International Classification of Diseases, Tenth Revision (ICD-10), code for Clostridioides difficile infection…”
Get full text

A Retrospective Assessment of Guideline Adherence and Treatment Outcomes From Clostridioides difficile Infection Following the IDSA 2021 Clinical Guideline Update: Clostridioides difficile Infection by Dubberke, Erik R, Li, Qinghua, Obi, Engels N, Turzhitsky, Vladimir, Siddiqui, Fakhar, Nathanson, Brian H

“…The 2021 update to the Infectious Diseases Society of America infection (CDI) guidelines recommended fidaxomicin as the preferred treatment over vancomycin for…”
Get full text

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States by Jiang, Yiling, Sarpong, Eric M., Sears, Pamela, Obi, Engels N.

Get full text

Appropriate cleaning reduces potential risk of spore transmission from patients with Clostridioides difficile infection treated in outpatient infusion centers by Schroeder, Claudia P., Hengel, Richard L., Nathan, Ramesh V., Ritter, Timothy E., Obi, Engels N., Lancaster, Chris, Van Anglen, Lucinda J., Garey, Kevin W.

“…Patients with Clostridioides difficile infection (CDI) who receive treatment at outpatient infusion centers (OICs) pose a risk for spore transmission. We…”
Get full text

Health Care Costs for Patients with Heart Failure Escalate Nearly 3-Fold in Final Months of Life by Obi, Engels N, Swindle, Jason P, Turner, Stuart J, Russo, Patricia A, Altan, Aylin

“…Heart failure (HF) is a severe chronic disease with growing prevalence and health care burden as well as high mortality. End-of-life cost data for patients…”
Get full text

Patients' Self-Reported Value of Avoiding Key Heart Failure Outcomes Differs Based on Disease Knowledge by Chang, Chun-Lan, Hauber, A. Brett, Price, Mark, Whalley, Diane, Obi, Engels N

Get full text

Quantifying the relative importance to patients of avoiding symptoms and outcomes of heart failure by Hauber, A. Brett, Obi, Engels N., Price, Mark A., Whalley, Diane, Chang, Chun-Lan

“…Objective: To evaluate heart failure (HF) patients' disease knowledge and preferences for avoiding different disease outcomes. Methods: An online survey was…”
Get full text

Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes by Dubberke, Erik R, Puckett, Justin T, Obi, Engels N, Kamal-Bahl, Sachin, Desai, Kaushal, Stuart, Bruce, Doshi, Jalpa A

“…BackgroundThe 2017 Infectious Diseases Society of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) Clostridium (Clostridioides) difficile…”
Get full text

Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System by McDaniel, Lauren F., White, Melissa N., Obi, Engels N., Kohinke, Rose M., Lockhart, Ellen Rachel S., Chipriano, Damian J., Chen, Yiyun, Everson, Nathan A.

“…Introduction This study aimed to evaluate the clinical and economic outcomes of implementing a Clostridiodes difficile infection (CDI) Treatment Optimization…”
Get full text

Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013 by Stuart, Bruce C, Tom, Sarah E, Choi, Michelle, Johnson, Abree, Sun, Kai, Qato, Danya, Obi, Engels N, Zacker, Christopher, Park, Yujin, Arcona, Steve

“…To assess formulary decisions by Part D plans for selected newly approved drugs. Retrospective cohort study. Formulary placement and restrictions were…”
Get full text

Risk Factors Associated with Severe Clostridioides difficile Infection in Patients with Cancer by Francisco, Denise Marie A., Zhang, Liangliang, Jiang, Ying, Olvera, Adilene, Adachi, Javier, Guevara, Eduardo Yepez, Aitken, Samuel L., Garey, Kevin W., Peterson, Christine B., Do, Kim-Anh, Dillon, Ryan, Obi, Engels N., Jenq, Robert, Okhuysen, Pablo C.

“…Introduction Antibiotic use is a risk factor for Clostridioides difficile infection (CDI). Few studies have correlated use of prior antibiotic classes with…”
Get full text

Healthcare Costs Among Patients with Heart Failure: A Comparison of Costs between Matched Decedent and Survivor Cohorts by Obi, Engels N., Swindle, Jason P., Turner, Stuart J., Russo, Patricia A., Altan, Aylin

“…Introduction Prior research suggests increased costs during the final months of life, yet little is known about healthcare cost differences between patients…”
Get full text

HEALTHCARE COSTS AND RESOURCE UTILIZATION IN HEART FAILURE: DIFFERENCES BASED ON HEART FAILURE HISTORY by Swindle, Jason, Turner, Stuart J, Obi, Engels N, Blauer-Peterson, Cori, Wacha, Lynn A, Altan, Aylin

“…Methods: A retrospective study of medical and pharmacy claims data from a large US health plan (commercial and Medicare Advantage enrollees) was conducted…”
Get full text

RELATIONSHIP BETWEEN HEART FAILURE THERAPY AND COST BURDEN OF HEART FAILURE IN A MANAGED CARE POPULATION by Swindle, Jason, Obi, Engels N, Turner, Stuart J, Blauer-Peterson, Cori, Wacha, Lynn A, Altan, Aylin

“…Cohort assignment (2) was based on pharmacy claims for HF-related therapy (angiotensin-converting enzyme inhibitor, angiotensin-receptor blocker, beta blocker,…”
Get full text